Lineage Cell Therapeutics Statistics

Total Valuation

TLV:LCTX has a market cap or net worth of ILS 788.40 million. The enterprise value is 648.24 million.

Market Cap	788.40M
Enterprise Value	648.24M

Important Dates

The last earnings date was Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	228.36M
Shares Outstanding	n/a
Shares Change (YoY)	+22.42%
Shares Change (QoQ)	+1.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	177.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.44
PB Ratio	4.97
P/TBV Ratio	38.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.70
EV / Sales	17.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.31

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.05.

Current Ratio	4.08
Quick Ratio	3.96
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -71.51% and return on invested capital (ROIC) is -21.41%.

Return on Equity (ROE)	-71.51%
Return on Assets (ROA)	-13.17%
Return on Invested Capital (ROIC)	-21.41%
Return on Capital Employed (ROCE)	-25.48%
Revenue Per Employee	496,926
Profits Per Employee	-1.86M
Employee Count	77
Asset Turnover	0.11
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.15% in the last 52 weeks. The beta is 1.66, so TLV:LCTX's price volatility has been higher than the market average.

Beta (5Y)	1.66
52-Week Price Change	+2.15%
50-Day Moving Average	325.48
200-Day Moving Average	233.63
Relative Strength Index (RSI)	51.62
Average Volume (20 Days)	18,640

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	11.34

Income Statement

In the last 12 months, TLV:LCTX had revenue of ILS 36.77 million and -137.84 million in losses. Loss per share was -0.62.

Revenue	36.77M
Gross Profit	-7.30M
Operating Income	-68.72M
Pretax Income	-137.33M
Net Income	-137.84M
EBITDA	-66.60M
EBIT	-68.72M
Loss Per Share	-0.62

Full Income Statement

Balance Sheet

The company has 142.48 million in cash and 7.26 million in debt, giving a net cash position of 135.22 million.

Cash & Cash Equivalents	142.48M
Total Debt	7.26M
Net Cash	135.22M
Net Cash Per Share	n/a
Equity (Book Value)	158.73M
Book Value Per Share	0.71
Working Capital	111.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -76.00 million and capital expenditures -1.98 million, giving a free cash flow of -77.99 million.

Operating Cash Flow	-76.00M
Capital Expenditures	-1.98M
Free Cash Flow	-77.99M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	-19.86%
Operating Margin	-186.87%
Pretax Margin	-373.45%
Profit Margin	n/a
EBITDA Margin	-181.13%
EBIT Margin	-186.87%
FCF Margin	n/a

Dividends & Yields

TLV:LCTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.42%
Shareholder Yield	n/a
Earnings Yield	-17.48%
FCF Yield	-9.89%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:LCTX has an Altman Z-Score of -4.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.91
Piotroski F-Score	4